Novo Nordisk's European shares plunged 18%, CEO admits: Facing "unprecedented pricing pressure" in 2026
Denmark’s pharmaceutical giant Novo Nordisk is facing its most severe performance challenge in nearly a decade, with the company forecasting a significant decline in sales in 2026 as market competition intensifies. On February 4, CEO Mike Doustdar stated bluntly, "The company will face unprecedented pricing pressure in 2026,